Skip to main content

Early blood test linked to later MS disability worsening

By MS Buddy ·

Summarized from JAMA neurology, Apr 2023 · PubMed · DOI. AI-generated summary. Not medical advice.

Observational study · 578 people after a first MS-like attack at Spanish hospitals

Research by Enric Monreal, Luisa María Villar and 26 colleagues at Universidad de Alcalá, Institut d'Investigacions Biomèdiques August Pi i Sunyer and Universitat de Barcelona and 7 other institutions in Spain.

Can a blood test after a first MS-like attack predict later disability worsening?

Key Takeaway

Higher levels of a blood marker after a first MS-like attack were linked to greater disability worsening years later.

Blood cells and small particles beside myelinated nerve fibers in a muted scientific illustration.
Credibility
Interest
Share:1 min read

What They Found

Researchers measured a blood marker of nerve damage within the first year after a first MS-like attack. People with higher levels were more likely to have disability that worsened and stayed worse for six months. They were also more likely to reach a higher level of disability on a doctor's rating scale. The link appeared in both groups of patients studied at Spanish hospitals. Among people with high marker levels, stronger MS treatments were linked to a lower risk of disability worsening.

Who Should Care and Why

The study followed people in Spain after their first MS-like attack. It focused on whether an early blood test could help predict later disability. Researchers checked patients at least every six months. They followed patients for about seven years, on average. The findings may help identify people at greater risk of disability worsening, but the test's role in treatment decisions remains uncertain.

Important Considerations

This observational study followed 578 people and did not assign treatments. You cannot tell from these findings whether stronger MS treatments caused the lower risks seen among people who received them. The study does not show whether using this blood test to choose treatment improves outcomes.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in JAMA neurology by et al.. Reproduced from the PubMed record.

The value of serum neurofilament light chain (sNfL) levels for predicting long-term disability in patients with multiple sclerosis (MS) remains controversial. To assess whether high sNfL values are associated with disability worsening in patients who underwent their first demyelinating MS event. This multicenter cohort study included patients who underwent their first demyelinating event suggestive of MS at Hospital Universitario Ramón y Cajal (development cohort; June 1, 1994, to September 31, 2021, with follow-up until August 31, 2022) and 8 Spanish hospitals (validation cohort; October 1, 1995, to August 4, 2020, with follow-up until August 16, 2022). Clinical evaluations at least every 6 months. The main outcomes were 6-month confirmed disability worsening (CDW) and an Expanded Disability Status Scale (EDSS) score of 3. Levels of sNfL were measured in blood samples obtained within 12 months after disease onset using a single molecule array kit. The cutoffs used were sNfL level of 10 pg/mL and a standardized score (z score) of 1.5. Multivariable Cox proportional hazards regression models were used to evaluate outcomes. Of the 578 patients included in the study, 327 were in the development cohort (median age at sNfL analysis, 34.1 years [IQR, 27.2-42.7 years]; 226 female [69.1%]) and 251 patients were in the validation cohort (median age at sNfL analysis, 33.3 years [IQR, 27.4-41.5 years]; 184 female [73.3%]). The median follow-up was 7.10 years (IQR, 4.18-10.0 years). Levels of sNfL greater than 10 pg/mL were independently associated with higher risk of 6-month CDW and an EDSS of 3 in the development cohort (6-month CDW: hazard ratio [HR], 2.39; 95% CI, 1.39-4.12; P = .002; EDSS of 3: HR, 4.12; 95% CI, 2.18-7.77; P < .001) and the validation cohort (6-month CDW: HR, 1.61; 95% CI, 1.07-2.42; P = .02; EDSS of 3: HR, 2.03; 95% CI, 1.23-3.33; P = .005). Highly effective disease-modifying treatments were associated with lower risks of 6-month CDW and an EDSS of 3 in patients with high baseline sNfL values. This cohort study found that high sNfL values obtained within the first year of disease were associated with long-term disability worsening in MS, suggesting that sNfL level measurement may help identify optimal candidates for highly effective disease-modifying treatments.

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Two matching brain lesion shapes, with a central vein faint on the left and more clearly visible on the right.
Adjusted MRI spots more veins inside MS brain lesions

11/18/2026

An adjusted MRI scan found more veins within MS brain lesions in 17 people with MS. It improved scan

Read More
Muted blue and clay ribbons curve across an off-white background, wrapped in soft layers of varying thickness.
Planned MS study will test scans to track worsening

11/16/2026

A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS

Read More
Muted branching paths cross translucent layers, revealing a small irregular pattern at their overlap.
Brain scans after a car crash revealed MS in a teen

1/1/2026

After a car crash, brain and spine scans revealed signs of MS in an 18-year-old male. Further tests

Read More
Brain outline with connecting fibers between its halves, some subtly lighter than others.
MS brain scans cannot confirm nerve signal failure

11/14/2026

An opinion paper explains why MS brain scans can show tissue loss without proving nerve signal failu

Read More
Layered paper circles hold faint abstract shapes on a warm neutral background.
Virus blood tests showed past exposure in Brazilian MS

11/15/2026

In 70 people with MS in Brazil, blood tests often showed signs of past viral exposure. Results did n

Read More
A simple eye leads to several paths; one reaches an abstract brain-and-spine shape.
Some with first optic nerve inflammation later had MS

11/12/2026

In a study of 601 people in Japan after first optic nerve inflammation, some later had MS. Others ha

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.